LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Nature Medicine today published a study showing that Perspectum's iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac ...

To advance the understanding and treatment of liver disease by pursuing innovative, transformative basic and translational ...

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...

FibroNest digital pathology in liver biopsies from patients with MASH FibroNest digital pathology augmented image for ...

A new study published in the New England Journal Of Medicine claimed that it can tackle non-alcoholic steatohepatitis or NASH ...

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

Despite growing policy uncertainty, plenty of healthcare companies have managed to put up big returns, thanks to these ...

We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...

Dawn Health and Merck have launched the next-generation digital ecosystem for growth disorders, designed to support patients with Growth Hormone Deficiency (GHD), their caregivers, and healthcare ...